PSMA PET/CT检出寡转移前列腺癌仅行转移灶定向放疗的肿瘤学结局
本研究回顾性评估激素敏感、异时性寡转移前列腺癌患者接受转移灶定向放疗(MDRT)的肿瘤学结局。80例患者共105个PSMA PET/CT确认病灶接受MDRT,中位随访32个月后仅10%患者PSA不可测、10%有PSA反应、80%出现生化进展,1年和2年bPFS率分别为54%和38%,87%患者局部控制但72%出现新转移灶。
要点
- MDRT对PSMA PET/CT检出的寡转移灶局部控制率高(87%)。
- 多数患者仍出现生化进展(80%)及新发转移灶(72%)。
- 1年和2年bPFS率分别为54%和38%,需关注远处进展。
核心结论
- MDRT对寡转移病灶局部疗效高,但相当比例患者仍出现疾病进展。
研究设计与样本
- 回顾性评估激素敏感、异时性寡转移前列腺癌患者,2012年7月至2022年9月因生化复发接受MDRT。
- 患者PSMA PET/CT显示1至4个淋巴结和/或骨转移,放疗剂量为5×7 Gy或3×10 Gy。
- 共80例患者接受MDRT,治疗105个PSMA PET/CT确认病灶。
主要发现
- 从根治性治疗至MDRT的中位时间为55个月(IQR 31-103)。
- MDRT后中位随访32个月(IQR 21-64),10%患者PSA不可测,10%有PSA反应,80%出现生化进展。
- 1年和2年bPFS率分别为54%和38%。
- 87%患者达到局部控制,72%患者在重复PSMA PET/CT上出现新转移灶。
关键数值与推荐
- 生化反应评估:随访PSA不可测、PSA反应(PSA≤治疗前水平)或生化进展(PSA>治疗前水平)。
- 局部缓解定义为随访PSMA PET/CT上MDRT部位无病灶或PSA不可测。
临床怎么用
- MDRT可作为PSMA PET/CT检出寡转移前列腺癌的局部治疗选择,但需密切监测生化进展和新发转移。
局限性
- 回顾性设计。
- 队列样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: In patients with biochemical recurrence (BCR), prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) can detect oligometastatic prostate cancer (PCa). However, the optimal treatment approach for oligometastatic disease remains unclear. This study aims to assess the oncological outcomes of metachronous oligometastatic PCa patients treated with metastasis-directed radiotherapy (MDRT). METHODS: We retrospectively evaluated patients with hormone-sensitive, metachronous oligometastatic PCa who underwent MDRT for BCR (from July 2012 to September 2022). Patients had one to four lymph nodes and/or bone metastases on PSMA PET/CT and were irradiated with 5 × 7 or 3 × 10 Gy. The biochemical response to MDRT was assessed as undetectable prostate-specific antigen (PSA) at follow-up, PSA response (PSA ≤ pretreatment level), or biochemical progression (PSA > pretreatment level). Biochemical progression-free survival (bPFS) and local remission of disease (absence of disease at the MDRT site on follow-up PSMA PET/CT or undetectable PSA) were evaluated. KEY FINDINGS AND LIMITATIONS: Eighty patients underwent MDRT for 105 PSMA PET/CT-confirmed lesions. The median time from curative treatment to MDRT was 55 mo (interquartile range [IQR] 31-103). At a median follow-up of 32 mo after MDRT (IQR 21-64), 10% of the patients were PSA free, 10% had a PSA response, and 80% experienced biochemical progression. The bPFS rates at 1 and 2 yr were 54% and 38%, respectively. A total of 87% of patients had local control of disease after MDRT, whereas 72% had new metastatic lesions on repeated PSMA PET/CT. Limitations include the retrospective design and a small cohort. CONCLUSIONS AND CLINICAL IMPLICATIONS: MDRT for oligometastatic disease shows high local efficacy. However, disease progression is observed in a substantial proportion of patients.
引用
- de Bie KCC, Zuur LG, Meijer D, et al. Oncological Outcomes in Patients with Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-detected Oligometastatic Prostate Cancer Treated with Metastasis-directed Radiotherapy as the Single Treatment Modality. Eur Urol Oncol. 2025. PMID: 40287345. doi:10.1016/j.euo.2025.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。